{"id":50675,"date":"2022-11-09T18:02:39","date_gmt":"2022-11-09T17:02:39","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/immunome-presents-preclinical-data-on-novel-anti-epn1-antibody-imm20059-at-the-society-for-immunotherapy-of-cancers-sitc-37th-annual-meeting\/"},"modified":"2022-11-09T18:02:39","modified_gmt":"2022-11-09T17:02:39","slug":"immunome-presents-preclinical-data-on-novel-anti-epn1-antibody-imm20059-at-the-society-for-immunotherapy-of-cancers-sitc-37th-annual-meeting","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/immunome-presents-preclinical-data-on-novel-anti-epn1-antibody-imm20059-at-the-society-for-immunotherapy-of-cancers-sitc-37th-annual-meeting\/","title":{"rendered":"Immunome Presents Preclinical Data on Novel Anti-EPN1 Antibody IMM20059 at the Society for Immunotherapy of Cancer\u2019s (SITC) 37th Annual Meeting"},"content":{"rendered":"
\n

\n– IMM20059, Immunome\u2019s epsin 1 (EPN1)-specific antibody, binds to the surface of multiple tumor cell lines, including lung, breast and prostate cancers in preclinical testing –<\/i>\n<\/p>\n

\n– EPN1 appears to play an important role in cancer formation and progression, and IMM20059 may have the ability to improve response to immunotherapy –<\/i>\n<\/p>\n

\n– Combinatorial effect (> 50% reduction in tumor volume) was demonstrated with IMM20059 and anti-PD-L1 treatment atezolizumab –<\/i>\n<\/p>\n

EXTON, Pa.–(BUSINESS WIRE)–Immunome, Inc. (Nasdaq: IMNM), a clinical-stage biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, today announced that it is presenting a poster at the Society for Immunotherapy of Cancer\u2019s (SITC) 37th<\/sup> Annual Meeting in Boston, Massachusetts highlighting the Company\u2019s preclinical data of IMM20059, a novel anti-epsin 1(EPN1) antibody.\n<\/p>\n

\n\u201cWe continue to be pleased with the robust capabilities of our Discovery Engine to identify novel anti-tumor targets, including those that are abnormally (ectopically) expressed on tumor cells which have the potential to fundamentally shift treatment paradigms,\u201d commented Purnanand Sarma, PhD, President and CEO of Immunome. \u201cWhile further preclinical work will be required, we are quite encouraged by the results presented at SITC today. Treatment with the IMM20059 + atezolizumab combination resulted in over a 50% reduction in tumor volume (p<0.05) compared to isotype-treated control, greater than either one separately. This leads us to believe that there is a potential combinatorial effect between the two pathways, and we look forward to exploring this phenomena further in additional pre-clinical studies.\u201d\n<\/p>\n

\nLack of response and immunoresistance to checkpoint inhibitors is a well-known challenge in cancer treatment. While the epsin-1 protein is known to be upregulated in a variety of tumor types, it can also be ectopically expressed on the tumor cell surface, as demonstrated in Immunome\u2019s poster, offering a new approach to cancer therapy. Insights into the role of epsin-1 as a potential target for cancer is evolving, but research by others1<\/sup> also suggests targeting EPN1 has the potential to inhibt tumor growth. The findings presented by Immunome at SITC further suggest that combining an EPN1-targeting antibody, like IMM20059, with checkpoint inhibitor treatment could reactivate or increase immune response to the tumor.\n<\/p>\n

\nImmunome Poster at SITC Annual Meeting (November 8-12, 2022):<\/b>\n<\/p>\n

\nTitle:<\/b> IMM20059, a novel anti-EPN1 antibody, in combination with atezolizumab significantly enhances tumor regression in the B16.F10 syngeneic melanoma model compared to anti-PD-L1 monotherapy
\n
Authors:<\/b> Fang Shen, PhD, John P. Dowling, Pavel A. Nikitin, Cezary R. Swider, Chris Nicolescu, Halley Shukla, Jamie L. Bingaman-Steele, Nirja B. Patel, Eden L. Sikorski, Benjamin C. Harman, Jillian M. DiMuzio, Karen Lundgren, Yumi Ohtani, Michael J. Morin, Matthew K. Robinson
\n
Link:<\/b> https:\/\/jitc.bmj.com\/content\/10\/Suppl_2\/A858<\/a>
Date\/Time: <\/b>Nov. 10, 2022\/9:00am
\n
Poster\/Abstract Number:<\/b> 823\n<\/p>\n

\nThe poster presentation, IMM20059, a novel anti-EPN1 antibody, in combination with atezolizumab significantly enhances tumor regression in the B16.F10 syngeneic melanoma model compared to anti-PD-L1 monotherapy<\/i>, highlights novel discoveries related to combinatorial activity between existing immune checkpoint inhibitors and the novel tumor target epsin 1 (EPN1).\n<\/p>\n

\nImmunome\u2019s preclinical research of IMM20059 in this poster demonstrated that:\n<\/p>\n